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Abstract
Background: Activin-A may exert pro- or anti-tumorigenic activities depending on cellular context. However, little
is known about its role, or the other mature activin proteins, in colorectal carcinoma (CRC). This study measured
the expression of activin βA- & βB-subunits, activin type IIA & IIB receptors, smads 2/3/4/6/7 and follistatin in CRC
induced by azoxymethane (AOM) in rats. The results were compared with controls and disseminated according to
the characteristics of histopathological lesions.
Methods: Eighty male Wistar rats were allocated into 20 controls and the remaining were equally divided between
short ‘S-AOM’ (15 weeks) and long ‘L-AOM’ (35 weeks) groups following injecting AOM for 2 weeks. Subsequent to
gross and histopathological examinations and digital image analysis, the expression of all molecules was measured
by immunohistochemistry and quantitative RT-PCR. Activin-A, activin-B, activin-AB and follistatin were measured by
ELISA in serum and colon tissue homogenates.
Results: Colonic pre-neoplastic and cancerous lesions were identified in both AOM groups and their numbers and
sizes were significantly (P < 0.05) greater in the L-AOM group. All the molecules were expressed in normal colonic
epithelial cells. There was a significantly (P < 0.05) greater expression of βA-subunit, IIB receptor and follistatin in
both pre-neoplastic and cancerous tissues. Oppositely, a significant (P < 0.05) decrease in the remaining molecules
was detected in both AOM groups. Metastatic lesions were only observed within the L-AOM group and were
associated with the most significant alterations of all molecules. Significantly higher concentrations of activin-A and
follistatin and lower activin-AB were also detected in both groups of AOM. Tissue and serum concentrations of
activin-A and follistatin correlated positively, while tissue activin-AB inversely, and significantly with the numbers
and sizes of colonic lesions.
Conclusions: Normal rat colon epithelial cells are capable of synthesising, controlling as well as responding to
activins in a paracrine/autocrine manner. Colonic activin systems are pathologically altered during tumorigenesis
and appear to be time and lesion-dependent. Activins could also be potential sensitive markers and/or molecular
targets for the diagnosis and/or treatment of CRC. Further studies are required to illustrate the clinical value of
activins and their related proteins in colon cancer.
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Background
Colorectal cancer (CRC) is a common malignancy asso-
ciated with high mortality rates [1]. Several treatment
modalities for CRC are available and include surgery,
chemotherapy and/or radiotherapy [2, 3]. Nevertheless,
the success and five year survival rates following the use
of the different therapeutic approaches are mainly
dependent on early diagnosis/intervention, since the
majority of treatment regimens are associated with lim-
ited efficacy and relatively low survival rates during
advanced stages of CRC [2, 3]. Additionally, resistance
against several recently introduced chemotherapeutic
agents in combination with 5-Fluorouracil has been re-
ported by many clinical trials, rendering chemotherapy
ineffective in a substantial number of patients [4, 5].
Therefore, a better understating of the biology of CRC
and its underlying pathophysiological pathways is essen-
tial for the development of alternative/complementary
effective therapeutic strategies [6, 7].
Several molecular pathways are pathologically skewed
during colon tumorigenesis [8]. Among these pathways,
the members of transforming growth factor (TGF)-β
family have recently been suggested as potential stage-
dependent targets for the treatment of CRC and/or
prevention of resistance associated with chemotherapy
[9]. Activins belong to the TGF-β family and the mature
activins consist of hetero- or homodimers of 2 β-
subunits (βA and βB) resulting in three distinct proteins
named activin-A (βA-βA), activin-B (βB-βB) and activin-
AB (βA-βB) [10]. The canonical pathway for activins,
following the activation of their type II receptors
(ACTRIIA & ACTRIIB), shares the same intracellular
mediators with TGF-β and both are dependent on
smad2, 3 and 4 [11]. Several extra- and intracellular
mechanisms for the control of activins bioactivities have
been described. Extracellular neutralising molecules
include the well-established activin binding protein,
follistatin, which binds the three mature isoforms of acti-
vin with similar affinity and prevents their interactions
with type II receptors [12]. Physiological intracellular
inhibitors of activins and TGF-β signals are known as
inhibitory smads (smad6 & 7) and both inhibit the
phosphorylation of receptor smads (smad2 & 3), pre-
vent their interactions with smad4 as well as induce
the degradation of activated activin and TGF-β type I
receptors [11].
In vitro studies suggested anti-tumour activities for
activin-A on several colon cancer cell lines through
smad2/3/4 pathway [13, 14]. The results from human
studies have further shown that malignant enterocytes
develop resistance to activin mainly by inducing muta-
tions in the activin type IIA receptor or the smad4-
dependent pathway [15, 16]. Restoration of the receptor
in vitro resulted in smad4-dependent growth inhibitory
effects and cell cycle arrest of cancerous enterocytes but
also induced their migration [17, 18]. Other studies in
human have also outlined that the serum concentrations
of activin-A correlate positively with tumour size, pro-
gression, invasiveness and inversely with survival rates
[19–21].
At the present time, none of the available in vitro and
human studies measured the role(s) of the other mature
activin isoforms and/or follistatin in colonic malignan-
cies. Additionally, there is no data in the literature on
the expression of activins and their related molecules in
experimental animal models of CRC. Azoxymethane
(AOM)-induced CRC in rodents is a well-established
and commonly used model for the study of the mo-
lecular biology, prevention and treatment of CRC.
This model imitates highly similar histopathological
features and shares similar molecular pathways to the
sporadic phenotype of CRC in human and, adenocar-
cinoma usually develops after 14 weeks of AOM
injection in rodents [8, 22].
The present study therefore measured the expression
of activin β-subunits, type II receptors, smads 2/3,
smad4 and smads 6/7 at the gene and protein levels in
early (15 weeks) and late (35 weeks) models of CRC in-
duced by AOM in rats. The results were also correlated
with the types and sizes of lesions. A better understand-
ing of the roles of activins and their related molecules in
colonic tumorigenesis may result in the development of
more effective early diagnostic and/or therapeutic
modalities for this common and deadly malignancy.
Methods
Study design
The study was approved by the Committee for the Care
and Use of Laboratory Animals at Umm Al-Qura Uni-
versity. A total of 80 adult male Wistar rats of 10 weeks
of age and 200–250 g/each were housed in clean and
sterile polyvinyl cages (five rats/cage), maintained on
standard laboratory pellet diet and water ad libitum; and
kept in a temperature-controlled air-conditioned at 22–
24 °C and 12 h dark/light cycle. The rats were randomly
categorised following acclimation for 1 week into 20
rats that served as ‘Control group’ and the remaining
60 animals were allocated equally for the 15 weeks
‘S-AOM’ group and 35 weeks ‘L-AOM’ group for the
short and long studies, respectively. AOM (Sigma-
Aldrich, MO, USA) was dissolved in normal sterile
saline and injected subcutaneously into the animals
at a dose of 15 mg/kg/week for a total of 2 weeks to
induce colon neoplasia as previously described [23].
Euthanasia was carried out using diethyl ether (Fisher
Scientific UK Ltd, Loughborough, UK) for anaesthesia
and 3 ml of blood were immediately collected from each
rat in a plain tube through the vena cava and the
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obtained serum were stored in −20 °C till used. The
colon from each animal was resected, incised through its
longitudinal axis and was then submerged in 10 % for-
malin overnight between layers of filter papers with the
mucosa facing upwards. The surface area for each colon
was calculated as follow: Length X Width in cm2. All
specimens were then processed for gross and histo-
pathological examinations and later for immunohisto-
chemistry, ELISA and gene expression studies.
Gross and microscopic quantification of tumours
The average numbers of tumours on the mucosal surface
of each colon were calculated by naked eye examination
by two observers and who were blind to the source of
tissues. Each colon was then cut equally into proximal,
middle and distal segments. All segments were stained
with 0.2 % methylene blue solution for 1.5–2 min, exam-
ined by a dissecting microscope (Human Diagnostics,
Germany) at × 20 magnification to calculate the numbers
of small tumours that were not detected by gross exam-
ination as well as aberrant crypt foci (ACF) and flat ACF
by 2 blinded examiners to the source animals and ac-
cording to the previously published criteria [24]. The
final numbers of micro-tumours and ACF were calcu-
lated by averaging the results of both observers. The
surface areas of ACF and flat ACF were calculated in
mm2 using ImageJ software (https://imagej.nih.gov/ij/)
(Additional file 1: Figure S1) [25, 26].
Two colonic specimens of 15 mm length and 4 mm
width from each of the 3 colonic segments (proximal,
middle and distal)/rat were excised under the dissecting
microscopy and the collected tissues were processed for
histopathological and immunohistochemical experi-
ments. One specimen was placed in cross-sectional
orientation and the other for topographic view. The
remaining tissues were kept in in 15 ml of RNALater
(Thermo Fisher Scientific, CA, USA) following distain-
ing and preserved in −80 °C till processed for quantita-
tive RT-PCR or total protein extraction by RIPA lysis
buffer.
Histopathological staining and examination
Tissue specimens from each colonic segment were proc-
essed by a conventional method, cut in 5 μm serial sec-
tions following embedding in paraffin, and stained by
haematoxylin and eosin for histopathology. All sections
were also stained according to the previously established
protocol with 1 % Alcian blue (AB) in 3 % acetic acid
followed by Neutral red counterstaining for the detec-
tion of mucin depleted foci (MDF) [27, 28].
The glandular cellular morphology as well as the num-
bers of ACF/MDF were examined on an EVOS XL Core
microscopy (Thermo Fisher Scientific). MDF were char-
acterised by the absence of blue staining within colonic
goblet cells of aberrant crypt foci as previously described
[27, 28]. ACF were microscopically classified according
to the previously established criteria into hyperplastic or
dysplastic [23]. Colonic adenomas consisted of prolifera-
tive/hyperplastic colonic glands, while adenocarcinoma
was characterised by dysplastic glands that invaded the
submucosal muscle layer [22]. All the lesions were char-
acterised and counted in five random fields from each
section by an expert histopathologist who was blind to
the specimen group. The total numbers of ACF and
MDF per colon were calculated by summing the results
from the 3 segments of each colon. The surface areas
of MDF (×200 magnification), adenoma and adenocar-
cinomas (×100 magnification) were calculated in μm2
(Additional file 2: Figure S2) using ImageJ [25, 26].
Immunohistochemistry
Primary polyclonal rabbit IgG antibodies (Santa-Cruz
Biotechnology Inc., CA, USA) were used for the detec-
tion of activin βA-subunit, βB-subunit, ACTRIIA,
ACTRIIB, phosphorylated (p)-smads 2&3, smad4, smads
6&7 and follistatin. Noteworthy, the antibody against
smad6 &7 does not differentiate between both types. An
avidin-biotin horseradish peroxidase technique was
applied to localise the molecules of interest using Immu-
noCruz™ Rabbit LSAB Staining System (Santa-Cruz Bio-
technology Inc.) and by following the manufacturer’s
protocol. The concentration was 1:100 for both activin
type II receptors, follistatin and smad4 antibodies while
a concentration of 1:50 was used for the remaining anti-
bodies. The negative control slides consisted of a section
of the tissue block being studied, which was treated
identically to all other slides, with the exception that the
primary antibodies were omitted to control for non-
specific binding of the detection system.
The sections were observed on an EVOS XL Core
microscope at × 100, ×200 and × 400 magnifications to
evaluate and score the immunostain. Each section was
examined by two observers who were blind to the source
of tissue and the intensity of staining was assessed in 5
random fields of each section at × 200 magnification and
by using ‘H score’ that was calculated as follow [23, 29]:
H score = Pί (ί +1), where ί represents the intensity of
staining (0 = negative; 1 = weak; 2 = moderate and 3 =
strong) and Pί is the percentage of cells (0–100 %)
stained at each intensity. In the case of a wide disagree-
ment between both observers, the slides were reanalysed
by a third independent reviewer.
Quantitative RT-PCR
The cDNA was synthesised by transcribing 200 ng of
total RNA using a high capacity RNA-to-cDNA Reverse
Transcription Kit (Thermo Fisher Scientific) according
the manufacturer’s protocol. PCR reactions were carried
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out in triplicate wells on ABI® 7500 system using power
SYBR Green master mix (Thermo Fisher Scientific). The
PCR reaction for each well included 10 μl SYBR
Green, 7 μl DNase/RNase free water, 1 μl of each pri-
mer (5 pmol) and 1 μl cDNA (25 ng) and, 40 cycles
(95 °C/15 s and 60 °C/1 min) of amplification were
performed. Two negative controls were included, one
with minus-reverse transcription (minus-RT) control
from the previous RT step and a minus-template
PCR, in which nuclease free water was used as a
template.
The 2-ΔΔCt method was used to perform relative quan-
titative gene expression of rat INHBA, INHBB, ACVR2A,
ACVR2B, FST, Smad2, Smad3, Smad4, Smad6 and
Smad7 target genes. Three reference genes were tested
and rat β-actin gene showed the most consistent results
and it was used to normalise the Ct values of the genes
of interest. The results are expressed as fold-change
compared with the control group. All used primers
(Additional file 3: Table S1) were designed in-house and
previously validated [29].
Enzyme linked immunosorbant assay (ELISA)
Two colonic tissue specimens of 50 mg each that in-
volved tumours (except for the control group) were sub-
merged in 2 ml RIPA lysis buffer with protease
inhibitors (Santa-Cruz Biotechnology Inc.) for protein
extraction using electrical homogeniser. All homoge-
nated samples were centrifuged at 14,000 rpm for
30 min at 4 °C and small aliquots (0.5 ml) of the result-
ant supernatant were placed in Eppendorf tubes. The
concentrations of total proteins in the colonic tissue
homogenates were measured at 280 OD on a BioSpec-
nano machine (Shimadzu Corporation, Japan). All pro-
tein samples were diluted by normal sterile saline for a
final concentration of 500 μg/ml of total protein.
The concentrations of activins and follistatin in serum
and tissue homogenates were measured using specific
ELISA kits (Cloud-Clone Corp., Houston, USA). All
samples were processed in duplicate on a fully auto-
mated system (Human Diagnostics, Germany) and by
following the manufacturer’s instructions. The detection
ranges were between 12.3 and 1000 pg/mL for both
activin-A & -B, 15.62–1000 pg/mL for activin-AB and
3.12–200 ng/mL for follistatin. The minimal detect-
able concentrations were 4.66 pg/mL for activin-A,
4.64 pg/mL for activin-B, 5.6 pg/mL for activin-AB
and 1.23 ng/mL for Follistatin. All kits had intra-
assay and inter-assay precisions of <10 % and <12 %,
respectively.
Statistical analysis
SPSS version 16 was used for the statistical analysis of
the results and, normality and homogeneity of data were
assessed by the Kolmogorov-Smirnov test and Levene
test, respectively. Student’s t test or Mann-Whitney U
test was used to compare between 2 groups based on
data normality. One way ANOVA followed by LSD
post hoc test were used to compare between the 3
groups. Correlations were determined by Pearson’s
test. P value < 0.05 was considered significant.
Results
Gross and histopathological features of AOM induced
colonic lesions
None of the rats from all groups died during the study
and tumours were detected by gross examination on the
mucosal surface of colons collected from both the short
and long study groups (Fig. 1; panels 1A, 2A and 3A).
The numbers of grown tumours detected by naked eye
was significantly higher (P = 0.003) in the L-AOM com-
pared with the S-AOM group (Table 1). Notably, en-
largement of regional lymph nodes (Fig. 1; panel 3A)
was also observed in 5 rats (16.7 %) of the L-AOM
group.
Examination under dissecting microscope following
methylene blue staining showed normal mucosal and
crypt appearance in the control group (Fig. 1; panel
1B). A significant increase in the numbers of large
ACF (>4 crypts/focus) in both the short (P = 0.0001)
and long (P = 0.03 × 10−5) compared with controls
was also observed (Table 1). Flat ACF was also de-
tected in both AOM groups, but not the control, and
the numbers were significantly higher (P = 0.002) in
long (Fig. 1; Panel 3B) compared with short (Fig. 1;
Panel 2B) AOM groups (Table 1). Similarly, the num-
bers of micro-tumours detected by dissecting micro-
scope (Table 1) were significantly higher (P = 0.006)
and had larger surface areas (P = 0.07 × 10−4) in the
L-AOM (Fig. 1; Panel 3C) compared with S-AOM
group (Fig. 1; Panel 2C).
MDF were present in the 2 groups of AOM either
in topographic (Fig. 1; panels 2F and 3F) or cross-
sectional (Fig. 1; panels 2G and 3G) orientations. The
numbers (P = 0. 02) and sizes (P = 0.0004) of MDF
were significantly higher in the L-AOM compared
with S-AOM group (Table 1). Additionally, large
MDF (>12 aberrant crypts/focus) were detected in
both groups of AOM and greater numbers of crypts/
focus were associated with the L-AOM group, reach-
ing to more than 50+ crypts/focus (Fig. 1; panel 3F)
compared with 20+ in the S-AOM group (Fig. 1;
panel 2F). Interestingly, cross-sectional specimens
showed several large MDF that were located at the
bottom end of the mucosa and beneath luminal
mucin-secreting glands (Fig. 1; panel 2G). All de-
tected MDF at the bottom end of colonic mucosa
showed features of high grade dysplasia (Fig. 1; panels
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2F, 2G and 3F). Additionally, the majority of adeno-
carcinomas in the L-AOM group were mucin de-
pleted (Fig. 1; panel 3G).
Multiple tubular adenomas that consisted of several
hyperplastic as well as dysplastic large ACF (>4 crypts/
focus) were observed by histopathology in the ‘S-AOM’
group (Fig. 1; panels 2 D & E). Growing in situ carcin-
oma were also detected in several rats (n = 7) within the
group and were characterised by large high-grade dys-
plastic ACF invading the lamina propria but not reach-
ing the muscularis mucosae (Fig. 1; panel 2E).





























Fig. 1 Features of colon mucosa by naked eye examination in (1A) control, (2A) S-AOM and (3A) L-AOM groups. Stained colonic mucosa with
0.2 % methylene blue from (1B) control, (2B & 2C) S-AOM and (3B & 3C) L-AOM groups to identify ACF and micro-tumours on the mucosal surface
by dissecting microscope (×20 magnification). Colonic tissue sections from (1C) control, (2D & 2E) short and (3D & 3E) long groups to characterise
the microscopic features at × 100 magnification following H&E stain. MDF were characterised at × 200 magnification and following staining with
1 % Alcian blue and Neutral red stains in (1D & 1E) normal, (2F & 2G) S-AOM and (3F & 3G) L-AOM in cross-sectional and topographic views,
respectively. (Black arrow = tumour observed by naked eye; red arrow = regional lymph node enlargement; red arrow head = flat ACF; yellow
arrow head =micro-tumour detected by dissecting microscope; black star = large ACF [>4 crypts/focus] with hyperplasia; red star = large
ACF with dysplastic features and green star = MDF)
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in the L-AOM group (Fig. 1; panel 3D). Moreover, me-
tastasis in the colonic serosa was seen in 6 rats (20 %) of
the group. The colonic serosa was identified microscop-
ically by the mesothelial cells and the detected meta-
static foci were characterised by the presence of well to
moderately differentiated colonic glands within the fatty
subserosal stroma located beneath the mesothelium
(Fig. 1; panel 3E).
Immunohistochemical characteristics of all molecules in
pre-neoplastic, benign and malignant colonic lesions
All target molecules were detected in normal colonic glan-
dular epithelium and showed cytoplasmic localisation, ex-
cept for p-smad2 (Fig. 3; middle column), p-smad3 (Fig. 3;
right column) and smad4 (Fig. 4; left column) which also
showed nuclear staining. Alterations in the immunostain
characteristics of the molecules of interest were seen in
the 2 AOM groups and were lesion-dependent (Table 2).
Overall, Significantly higher expression of activin βA-
subunit (Fig. 2; left column) were seen in the S-AOM
(257.1 ± 33.3; P = 0.03) and L-AOM (322.2 ± 37.7; P =
0.006) compared with control group (215.5 ± 31.1).
Additionally, there was a significant difference (P = 0.007)
between the early (Fig. 2; panels d a and g) and late (Fig. 2;
panels j and m) models of CRC in the expression of βA-
subunit. Similarly, activin type IIB receptor (Fig. 3; left
column) and follistatin (Fig. 4; left column) were signifi-
cantly increased in the S-AOM (264.4 ± 31.3; P = 0.007
and 318.8 ± 38.7; P = 0.002, respectively) and L-AOM
(357.2 ± 36.4; P = 0.008 and 347.7 ± 32.8; P = 0.005, re-
spectively) groups compared with controls (116.6 ± 26.7
and 237.6 ± 32.2, respectively). Significant alterations were
also detected for ACTRIIB (P = 0.03) and follistatin (P =
0.01) between both AOM groups.
In contrast, a significant decrease was observed in
the expression of activin βB-subunit (Fig. 2; middle
column), activin type IIA receptor (Fig. 2; right
column), p-smad2 (Fig. 3; middle column), p-smad3
(Fig. 3; right column), smad4 (Fig. 4; left column) and
smads 6&7 (Fig. 4; middle column) in both short and
long AOM compared with normal colons. Signifi-
cantly lower expressions in the L-AOM in compari-
son with S-AOM samples were also observed for βB-
subunit (93.9 ± 26.7 vs. 167.6 ± 51.1; P = 0.02),
ACTRIIA (82.3 ± 17.9 vs. 189.6 ± 57.7; P = 0.03) and
smad4 (111.4 ± 25.5 vs. 133.5 ± 32.1; P = 0.03). How-
ever, no difference (P > 0.05) was detected in p-smads
2&3 and smads 6&7.
Table 1 Mean ± SD of body weight, colon surface area (length X width in cm), count of colonic tumours by gross and dissecting
microscope, number of tumour/colon surface area ratio (NT/CS), numbers and median surface areas of large (≥4 crypts/focus) and







Body weight (g) 231.57 ± 20.01 221.97 ± 23.01 179.6 ± 15.64b,d
Colon surface area (cm2) 19.1 ± 2.2 18.89 ± 3.43 17.81 ± 1.84a
Tumour count Gross ND 7.2 ± 2.9 12.5 ± 3.21d
Dissecting Microscope ND 15.4 ± 5.1 24.8 ± 5.9d
Total N/A 23.1 ± 3.7 35.3 ± 4.1d
NT/CS Ratio N/A 1.33 ± 0.4 1.95 ± 0.2c
Dissecting microscope
(×20 magnification)
large ACF Numbers 1.1 ± 0.2 69.4 ± 10.2b 143.2 ± 26.1b,d
Median surface
area (mm2)
4.1 (range 2.4–7.1) 29.7 (range 7.3–42.4)b 85.3 (range 7.9–133.3)b,d
Flat ACF Numbers ND 18.4 ± 7.3 31.2 ± 9.6c
Median surface
area (mm2)
N/A 21.2 (range 8–51.7)b 69.4 (range 9.3–91.8) d
Light microscope MDF (×200
magnification)
Numbers ND 17.4 ± 3.1 29.1 ± 3.6d
Median surface
area (μm2)
N/A 161.5 (range 12.2–352.9) 596.4 (range 142.8–966.3)d
Adenoma (×100
magnification)
Numbers ND 9.8 ± 3.1 11.6 ± 2.8
Median surface
area (μm2)
N/A 353.6 (range 101.7–507.8) 728.3 (range 274.8–1396.7)d
Adenocarcinoma
(×100 magnification)
Numbers ND 16.7 ± 4.1 82.6 ± 15.7d
Median Surface
area (μm2)
N/A 107.9 (range 48–251.7) 711.8 (range 222.8–1808.4)d
N/A not applicable, ND not detected, aP < 0.05 compared with control; bP < 0.01 compared with control, cP < 0.05 compared with S-AOM group and dP < 0.01
compared with S-AOM group
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By further analysis according to the type of colonic le-
sions, there was a significant consistent increase in the
expression of activin βA-subunit, type IIB receptor and
follistatin between pre-neoplastic, benign and malignant
lesions. The expression values of all molecules according
to lesion types are summarised in Table 2.
Quantitative gene expression of activins and their related
molecules
Gene expression studies showed a significant increase in
the mRNA expression of INHBA (6 folds; P = 0.001),
ACVR2B (10.8 folds; P = 0.0003) and FST (3.1 folds; P =
0.02), and a significant decrease in the gene expression of
INHBB (2.3 folds; P = 0.02), ACVR2A (3 folds; P = 0.003),
smad2 (2.5 folds; P = 0.007), smad3 (2 folds; P = 0.03),
smad4 (4 folds; P = 0.0004), smad6 (3 folds; P = 0.003) and
smad7 (3.2 folds; P = 0.005) in the S-AOM group when
compared with the control tissues. The gene expression of
all candidate molecules, except for smads 2, 3 and 6, were
also significantly altered in the L-AOM compared with
the S-AOM group (Fig. 5).
Tissue and serum concentrations of mature activin
proteins and follistatin
The tissue homogenate concentrations of mature
activin-A, activin-AB and follistatin, but not activin-B,
proteins were significantly different between the 3 study
groups. A significant increase in activin-A (P = 0.004)
and follistatin (P = 0.06 × 10−3), while a significant de-
crease in activin-AB (P = 0.03) were detected in the
colon tissue homogenates from the S-AOM compared
with control group. A further increase in both activin-A
(P = 0.0003) and follistatin (P = 0.02) as well as a further
decrease in activin-AB (P = 0.03) was also statistically
significant in the tissue homogenates of L-AOM com-
pared with S-AOM group.
At the serum level, significant alterations were only
detected in the concentrations of activin-A (P = 0.007)
and follistatin (P = 0.03) between the short and control
groups. Serum samples from the L-AOM group had also
significantly higher concentrations of activin-A (P = 0.01)
and follistatin (P = 0.02) compared with the S-AOM
group. There was no significant change (P > 0.05) by one
way ANOVA in the serum concentrations of both
activin-B and activin-AB between the study groups
(Table 3).
Correlation studies showed significant strong positive
correlations for tissue activin-A and follistatin, and a sig-
nificant inverse correlation for tissue activin-AB with the
numbers and surface areas of large and flat ACF, MDF,
adenocarcinoma as well as the numbers of gross and
micro-tumours (Table 4).
Discussion
The present study simultaneously measured the expres-
sion of activins and their related proteins in rat colonic
tissues collected from AOM-induced colon cancer and
the results were compared with normal tissue obtained
from controls. The results of the molecules of interest
were further analysed between early and late stages of
CRC and were also correlated with the different types
and sizes of colonic neoplastic lesions.
AOM-induced CRC in murine is a well-recognised
and frequently used experimental model that shares
many of the molecular tumorigenic pathways underlying
the common sporadic form of human colon malignancy
[8, 22]. Herein, we used a variety of previously well-
established pre-neoplastic lesions to assess the initiation
and progression of cancer [30–33]. Our findings are in
parallel with the previously published characteristics of
premalignant and cancerous colonic lesions associated
with AOM model [30–33] Additionally, they support the
Table 2 Mean ± SD of immunohistochemistry scores for activin βA- and βB-subunits, type 2 receptors, phosphorylated (p)-smads2&3,
Smad4, smads6&7 and follistatin proteins in colon specimens from the different groups and according to pre-neoplastic (large ACF
and MDF), benign and malignant lesions
Control group S-AOM group L-AOM group
Normal gland Pre-neoplastic lesion Adenoma Carcinoma in situ Carcinoma Serosal metastatic carcinoma
βA-subunit 215.5 ± 31.1 296.8 ± 34.4b 255.1 ± 29.3a,c 313.3 ± 22.2b,d 334.1 ± 27.2b,c,d,e 363.7 ± 34.3b,c,d,e,f
βB-subunit 173.7 ± 28.7 113.4 ± 29.2b 227.2 ± 33.2a,c 129 ± 31.4b,d 122.8 ± 25.5b,c,d 73.7 ± 21 .9b,c,d,e,f
ACTRIIA 201.1 ± 26 137.2 ± 28.3b 234.7 ± 31.7a,c 103.3 ± 28.3b,c,d 93.4 ± 22.2b,c,d 68.8 ± 23.3b,c,d,e,f
ACTRIIB 116.6 ± 26.7 261.8 ± 37.7b 277.6 ± 31.6b 311.4 ± 22.8b,c,d 321.3 ± 28.9b,c.d 352.4 ± 27.6b,c,d,e,f
p-Smad2 192.4 ± 29.5 137.1 ± 26.8b 88.8 ± 21.7b,c 79.6 ± 25.3b.c 78.5 ± 22.9b,c 81.3 ± 18.8b,c
p-Smad3 272.7 ± 27.6 236.5 ± 42.6a 228.4 ± 47.4b 142.8 ± 43.6b,c,d 133.3 ± 39.3b,c,d 314.7 ± 32.2a,c,d,e,f
Smad4 226.7 ± 29.4 163.1 ± 27.2a 108.8 ± 33.1b,c 134.5 ± 35.3b,c 121.4 ± 38.4b,c 81.3 ± 22.2b,c,d,e,f
Samds6&7 166.8 ± 32.9 92.3 ± 21.7b 132.7 ± 31.3a,c 115.1 ± 21.3a,d 89.6 ± 23.3b.d.e 235.6 ± 42.2b,c,d,e,f
Follistatin 237.6 ± 22.2 272.3 ± 25.3a 291.4 ± 24.2b 317.8 ± 22.3b,c,d 333.8 ± 35.3b,c,d 365.8 ± 29.9b,c,d,e
aP < 0.05 compared with normal; bP < 0.01 compared with normal; cP < 0.05 with pre-neoplastic lesion subgroup; dP < 0.05 compared with adenoma subgroup;
eP < 0.05 with carcinoma in situ subgroup and fP < 0.05 compared with carcinoma subgroup
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earlier suggestion that these lesions are time-dependent
since the numbers and sizes of adenocarcinoma were
significantly higher in the L-AOM group and a minority
of animals had metastatic foci within the colonic serosa
and/or enlargement of regional lymph nodes [34].
However, MDF were detected in the present study by
a modified protocol using 1 % AB pH 2.5 in sectioned
rather than non-sectioned colonic specimens [28]. Inter-
estingly, AB staining of cross-sectional specimens
showed several MDF that were localised beneath luminal
colonic glands, which had normal morphology and
mucin contents, suggesting that substantial numbers of
these pre-neoplastic lesions could have been missed if
examination was performed in non-sectioned specimens.
Furthermore, the majority of glands in these deeply-
situated MDF showed dysplastic features similar to those
usually reported in MDF detected in un-sectioned speci-
mens [32, 33]. We therefore propose that the loss of
mucin secretion is initiated a the lower extremity of a
hyperplastic mucosal layer and later spreads to involve
luminal glands, which is aligned with the “shift upwards
theory” for colon carcinogenesis [35]. However, more
studies using Periodic Acid-Schiff with Alcian blue stain-
ing protocol for the detection and differentiation be-
tween neutral and acid mucins are required to support
our hypothesis [36].
The available reports on the expression of activins and






Fig. 2 Immunohistochemical expression of activin βA-subunit (left column), βB-subunit (middle column) and type IIA receptor (right column) in
normal colonic mucosa from control (a, b & c), pre-neoplastic lesions from S-AOM group (d to i), adenocarcinoma (j, k & l) and serosal metastatic
foci (m, n & o) from the L-AOM group. (Red star = large dysplastic ACF and yellow star =MDF; ×200 magnification, scale bar = 8 μm)
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are few and the majority only focused on activin-A. In
vitro studies have shown that activin βA-subunit is
expressed in epithelial cells from human embryonic and
rat small intestinal cells [37, 38]. Exogenous activin-A
inhibited cell proliferation and induced differentiation
of rat IEC-6 cells [37], decreased the growth of mice
m-ICc12 cells [39] while stimulated the proliferation
of colonic epithelial cells collected from developing
rats [40]. Nevertheless, others failed to detect activin
βA-subunit and/or showed weak immunostain in nor-
mal human colonic tissues despite the localisation of
activin receptors within the same samples [19, 41].
However, a significant increase in the expression of
βA-subunit has been shown in enterocytes from patients
with inflammatory bowel disease [41]. Similarly, studies
in mice also reported weak or no expression of βA-
subunit in normal colonic glands and the induction of
colitis resulted in a significant increase of the molecule
[39, 42]. The expression of both type IIA and IIB recep-
tors as well as smads 2&3 has also been detected in mice
normal colon epithelial cells and, a significant increase
in their production was noted during colitis and they
were co-localised with activin subunits within the same
cells [39]. Injecting follistatin in vivo also inhibited the
progress of inflammation [39, 42], while overexpression
of activin-A in vivo following injection of a plasmid
DNA containing βA-subunit cDNA in mice resulted in






Fig. 3 Immunohistochemical expression of activin IIB receptor (left column), phosphorylated smad2 (middle column) and smad3 (right column) in
normal colonic mucosa from control (a, b & c), pre-neoplastic lesions from S-AOM group (d to i), adenocarcinoma (j, k & l) and serosal metastatic
foci (m, n & o) from the L-AOM group. (Red star = large dysplastic ACF and yellow star =MDF; ×200 magnification, scale bar = 8 μm)
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intraepithelial localisation of βB-subunit in normal colon
has been reported by a single study and the expression
increased during colitis and was co-localised with the
βA-subunit [39].
Our study is in agreement and correlates with the
aforementioned reports since it demonstrated the
expression of activin subunits, activin type II recep-
tors, smads and follistatin at the gene and protein
levels by normal rat colonic enterocytes. The co-
localisation of both activins subunits with their recep-
tors observed by Zhang et al. [39] and ours advocates
that the colonic epithelial cells are cable of synthesis-
ing as well as controlling the biological activities of
activin proteins and provide further support to the
notion that activins are involved in the regulation of
colonic cellular physiology in a paracrine/autocrine
mode of action [37–43]. Furthermore, this study is
the first to detect the three mature activin isoforms
in tissue homogenates of rat normal colon. We there-
fore hypothesise that each of the mature activin pro-
teins could have unique physiological function(s) in
the regulation of colonic homeostasis since the results
from gene knockout experiments have shown that
activin subunits do not functionally intersect in all
settings in vivo [44, 45]. Further studies are, however,
still needed to explore and compare the effect(s) of
the different mature activin isoforms on the biology






Fig. 4 Immunohistochemical expression of smad4 (left column), smads 6&7 (middle column) and follistatin (right column) in normal colonic
mucosa from control (a, b & c), pre-neoplastic lesions from S-AOM group (d to i), adenocarcinoma (j, k & l) and serosal metastatic foci
(m, n & o) from the L-AOM group. (Red star = large dysplastic ACF and yellow star = MDF; ×200 magnification, scale bar = 8 μm)
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Fig. 5 Mean ± SD of messenger RNA relative expression of a βA-subunit, b βB-subunit, c IIA receptor, d IIB receptor, e smad2, f smad3,
g smad4, h smad6, i smad7 and j follistatin the different study groups. (a = P < 0.05 compared with control group; b = P < 0.05 compared
with S-AOM group)
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Colon homeostasis involves the regeneration and
maintenance of mucosal integrity and, both processes
require continuous cell production from the stem cell
niche located at the base of colonic crypts that later mi-
grate upwards and differentiate to fully functioning cells
[46]. Additionally, a delicate balance between cell pro-
duction and differentiation as well as apoptosis is tightly
regulated in the colon by several molecular pathways
[47]. Dysregulation in these pathways following a variety
of insults is believed to result in the development of
colon malignancy [23, 46, 47].
In deed deregulation of colonic endogenous activin
system could well be involved in colon carcinogenesis.
Activins play crucial roles in many cellular homeostatic
functions including cell proliferation and differentiation,
wound repair and regulation of immune responses [10].
Pathological increase in activin βA-subunit protein and
mRNA has been observed in malignant tissues obtained
from patients with CRC and the expression was stage-
dependent [19–21]. Furthermore, there was a significant
positive correlation between the expression levels of
INHBA mRNA and serum activin-A with lymph node
metastasis and the progression of malignancy, respect-
ively [20, 21]. The researchers have therefore proposed
serum activin-A as a potential sensitive and specific
prognostic marker for colon cancer [19–21]. Frameshift
mutations in the ACVR2 gene have also been associated
with microsatellite instable colon neoplasms [16–18].
Mutation inactivations of all the smads involved in the
intracellular canonical pathway shared by both activins
and TGF-β have also been documented during the pro-
gression of CRC in human [48–50].
The current findings are in agreement with the previ-
ous studies since they showed a significant increase in
the expression of βA-subunit as well as a significant de-
crease in type IIA receptor and all tested smads at the
protein and gene levels in tissues obtained from rat
colon cancer. Additionally, the highest expression of βA-
subunit and, the lowest expression of IIA receptor,
smad4 and smad7, was observed in the L-AOM group
especially in metastatic foci. Moreover, significantly
greater levels of ACTRIIB and follistatin concurred with
the observed increase of βA-subunit in malignant
tissues. Contrariwise, a significant downregulation of
Table 3 Mean ± SD of protein concentrations of activin-A,
activin-B, activin-AB and follistatin in serum and colon tissue
homogenates by ELISA
Normal group S-AOM group L-AOM group
Activin-A
(pg/mL)
Tissue 388.8 ± 61.7 586.4 ± 72.6b 862.3 ± 210.2b,d
Serum 266.5 ± 41.7 472.4 ± 63.3b 614.8 ± 111.4b,c
Activin-B
(pg/mL)
Tissue 337.8 ± 68 298.1 ± 54.7 315.2 ± 47.3
Serum 180.4 ± 43.3 191.2 ± 32.8 213.9 ± 56.5
Activin-AB
(pg/mL)
Tissue 277.4 ± 34.2 154.7 ± 41.4a 83.4 ± 24.2b,c
Serum 181.7 ± 62.8 172.9 ± 40.9 202.2 ± 77.8
Follistatin
(ng/mL)
Tissue 5.6 ± 1.8 15.2 ± 3.9b 38.01 ± 6.2b,d
Serum 3.83 ± 1.1 7.4 ± 2.3b 11.2 ± 2.9b,c
(aP < 0.05 compared with control; bP < 0.01 compared with control, cP < 0.05
compared with S-AOM group and dP < 0.01 compared with S-AOM group)
Table 4 Results of correlation analysis using Pearson’s test for tissue and serum concentrations of activin-A, activin-B, activin-AB and
follistatin with the numbers (N) and surface areas (SA) of the different types of colonic lesions (*P < 0.05)
Large ACF Flat ACF MDF Adenoma Carcinoma Tumours
N SA N SA N SA N SA N SA Gross Micro
Activin-A (pg/mL) Tissue R Value 0.123 0.271* 0.364* 0.288* 0.416* 0.383* 0.027 0.091 0.589* 0.471* 0.389* 0.352*
P Value 0.7 0.008 0.03 0.004 0.0001 0.003 0.9 0.8 0.003 0.02 0.02 0.03
Serum R Value 0.082 0.071 0.101 0.089 0.091 0.062 0.051 0.009 0.397* 0.312* 0.256* 0.299*
P Value 0.8 0.8 0.7 0.8 0.7 0.9 0.9 1 0.03 0.04 0.03 0.03
Activin-B (pg/mL) Tissue R Value −0.091 −0.103 −0.053 −0.071 −0.304* −0.218* −0.086 −0.091 −0.205* −0.171 −0.005 −0.091
P Value 0.7 0.7 0.5 0.6 0.002 0.03 0.3 0.4 0.03 0.1 0.9 0.4
Serum R Value 0.008 0.062 −0.003 −0.098 −0.004 −0.062 0.054 0.003 −0.037 0.011 0.063 0.019
P Value 0.9 0.8 0.8 0.8 0.9 0.7 0.7 0.9 0.5 0.7 0.6 0.5
Activin-AB (pg/mL) Tissue R Value 0.019 −0.032 0.062 0.051 −0.342* −0.288* 0.079 0.009 −0.377* −0.311* −0.289* −0.300*
P Value 0.8 0.8 0.4 0.4 0.002 0.01 0.3 0.9 0.009 0.02 0.007 0.006
Serum R Value 0.002 0.007 0.011 −0.092 −0.003 0.044 −0.007 −0.009 −0.104 −0.012 −0.100 −0.112
P Value 0.9 0.8 0.8 0.8 1 0.9 1 1 0.4 0.8 0.4 0.7
Follistatin (ng/mL) Tissue R Value 0.144 0.171 0.164* 0.118 0.389* 0.299* 0.007 0.009 0.498* 0.412* 0.311* 0.243*
P Value 0.08 0. 4 0.03 0.4 0.001 0.005 0.8 0.8 0.002 0.004 0.02 0.03
Serum R Value 0.002 0.051 0.091 0.009 0.001 0.055 0.062 0.019 0.333* 0.302* 0.187* 0.111
P Value 1 0.8 0.7 0.9 1 0.9 0.9 0.9 0.004 0.006 0.02 0.1
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activin βB-subunit corresponded with the decrease of
IIA receptor and the different smad proteins in the two
AOM groups. At the level of mature proteins, there was
an increase in activin-A as well as follistatin and a
decrease in activin-AB concentrations in colonic tissue
homogenates and both activin isoforms significantly and
paradoxically correlated with the numbers and sizes of
both pre- and cancerous lesions. These observations
suggest that, similar to human, the AOM-induced colon
cancer in rat is associated with a disruption of rat
colonic endogenous activin-A system, which appears to
be a pro-tumorigenic pathway of CRC in both species.
In addition, this study provides additional support to the
potential clinical value of serum activins-A as a prognos-
tic marker during colon malignancy [19–21].
Remarkably, our findings also propose that mature
activin-AB may have anti-carcinogenic activities since
there were significant inverse correlations between the
progression of colon cancer with the tissue concentra-
tions of the protein. In this regards, gene deletion of
activin βA- and βB-subunits resulted in completely
different phenotypes and the insertion of INHBB in
INHBA−/− mice partially restored the lost functions
[44, 45]. Additionally, there is a tremendous gap in our
knowledge and understanding of the potential physio-
logical and pathological roles of the other activin isoforms
(B & AB) in the different cells and tissues since the major-
ity of studies were mainly conducted on activin-A only
[10]. Nevertheless, a recent study has shown that patients
with breast cancer and were positive for epidermal growth
factor receptor 2/neu, which is a marker of carcinogenesis,
had significantly lower serum concentrations of activin-AB
[51]. Therefore, the role of the activin-AB in tumour biol-
ogy merits further research to explore its potential bio-
logical and anti-tumorigenic activities in the human colon.
Moreover, gene deletion studies have demonstrated
that ACVR2−/− null mice exhibited an entirely different
phenotype from those mice lacking type IIB receptor
[52, 53]. Interestingly, both models of activin type II re-
ceptors deficient mice also differed from those lacking
activin βA- or βB-subunits, suggesting that activin
ligands may possibly interact and signal through other
different receptors [44, 45]. Another study has also dem-
onstrated that the overexpression of activin βA-subunit
was associated with a decrease in the mRNA levels of
ACTRIIA in the testes of inhibin deficient mice [54].
Additionally, a pathological increase in activin-A and its
type IIB receptor has been shown to induce cancer cach-
exia and the use of a receptor decoy for blocking the
ACTRIIB lead to a significant restoration in the muscle
mass and increase in the survival rates of treated animals
[55]. Hence, we postulate that each of the mature activin
proteins may well have a preferential downstream intra-
cellular pathway during colon tumorigenesis, where over
production of activin-A could favour the activation of
receptor IIB while activin-AB may propagate its signal
via IIA receptor. Additionally, the intracellular propa-
gation of activin signals through each of the activin
type II receptors may possibly results in paradoxical
non-overlapping effects during the course of colon
carcinogenesis since the activation of type IIA results
in anti-tumorigenic activities while IIB receptor path-
way is pro-carcinogenic [17, 18, 55].
The associations between elevated activin-A and the
downregulation of smads appear to be complex, as one
of them could be simultaneously a cause and the other a
consequence. In this context, the findings of a recent
study using a xenograft model of oesophageal cancer
have shown that the pro- and anti-tumorigenic effects of
activin-A are concentration-dependent [56]. Hence, a
sustained pathological up-regulation in colonic activin-A
could favour the activation of other non-canonical intra-
cellular mediators, such as ERK, p38 and Akt, and thus
leading to a downregulation in the none-utilised smads
[57–59]. Alternatively, others have reported that malig-
nant enterocytes develop resistance to the growth inhibi-
tory effects of activin-A mainly by inducing mutations in
the ACTRIIA or the smad4-dependent pathway [15, 16].
Additionally, restoration of activin IIA receptor in vitro
resulted in smad4-dependent growth inhibitory effects
and cell cycle arrest of cancerous enterocytes but also
induced their migration following treatment with
activin-A [17, 18]. Therefore, it could be postulated that
inactivation of smads following gene mutations [48–50]
may result in hyper-physiological concentrations of
activin-A and subsequently the activation of non-
canonical pathways that involve several pro-carcinogenic
molecules [57–59]. Therefore, additional in vivo and in
vitro studies are mandatory to explore the interactions
between activins and their canonical and non-canonical
signal mediators in normal and cancerous colonic cells.
Other proposed mechanisms for the development of
resistance by tumour cells to the growth inhibitory
effects of activin-A include up-regulation of follistatin
[60, 61]. Our results showed significantly higher concen-
trations of follistatin at the gene and protein levels that
positively correlated with the progression of colon can-
cer in the used model. Currently there is no report in
the literature regarding the role of follistatin in colon
cancer. Nevertheless, our results suggest that the ob-
served increase in follistatin could be an independent
pro-oncogenic molecule. In support of the previous sug-
gestion, in vitro studies on prostate cancer have revealed
that the progression of tumour and development of re-
sistance to the growth inhibitory actions of activin-A
were associated with higher levels of follistatin [62, 63].
Alternatively, the up-regulation of follistatin may plaus-
ibly be a compensatory mechanism against the
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pathological increase of activin-A since a more recent
study has also reported that follistatin inhibited can-
cer progression in a subset of pancreatic cancer cell
lines that are known to highly express both activin β-
subunits [64].
Conclusions
Normal rat colonic glandular epithelial cells are capable
of synthesising and responding to the different mature
activins isoforms in a paracrine/autocrine mode of
action as well as tightly controlling the bioactivities of
these ligands at both the extra- and intracellular levels.
Additionally, colonic activin system is pathologically
altered and could be involved in colon tumorigenesis
and, the expression of activins appears to be time-
dependent and lesion-specific. The significant correla-
tions for serum and tissue activin-A and follistatin with
the types and sizes of neoplastic lesions provide further
support to the notion that these proteins could be sensi-
tive biochemical markers and/or potential molecular
targets for the diagnosis and/or treatment of colon can-
cer. Further studies are required to illustrate the clinical
value of activins and their related proteins in human
colon cancer.
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Additional file 1: Figure S1. Steps of processing the study digital
images with ImageJ software for calculating the surface areas of colonic
micro-tumours (left column) and flat ACF (middle column) detected by
dissecting microscopy following methylene blue staining; and MDF
(right column) by light microscopy following staining with 1 % Alcian
blue. The identification and selection of the areas of interest (2nd row
from top) were done with the guidance of an expert histopathologist.
The images were then processed using hue/saturation/brightness (HSB)
for colour threshold adjustment using ‘red’ as the threshold colour to
digitally mark and select an area of interest by the software (3rd row from
top). This was followed by transforming all the images to binary colours
to ensure that only the areas of interest were precisely defined and
selected by the software (bottom row). All measurements were calculated
following calibration with digital photos of corresponding microscopic scale
slides captured at the designated magnifications. (Panels 1A-E and 2A-E:
×20 magnification, scale bar = 2 mm; panels 3A-E: ×200 magnification, scale
bar = 8 μm). (PPTX 1499 kb)
Additional file 2: Figure S2. Steps of processing the study digital
images with ImageJ software for calculating the surface areas of colonic
adenoma (left column; ×100 magnification), carcinoma in situ (middle
column; ×100 magnification) and adenocarcinoma (right column; ×200
magnification) observed by light microscopy and following staining with
haematoxylin & eosin. The areas of interest were also selected with the
support of an expert histopathologist (2nd row from top), then processed
for colour threshold adjustment using HSB and ‘red’ as threshold colour
(3rd row from top) and, finally all the images were transformed to binary
colours in which the areas of interest appear in solid black colour
(bottom row). All measurements were calculated following calibration
with digital photos of corresponding microscopic scale slides captured at
the designated magnifications. (Panels 1A-E and 2A-E: ×100 magnification,
scale bar = 15 μm; panels 3A-E × 200 magnification, scale bar = 8 μm).
(PPTX 1748 kb)
Additional file 3: Table S1. Contains the sequence of forward and
reverse primers for the detection of target genes along with the
amplicon sizes. (DOC 44 kb)
Additional file 4: Histopathology, immunohistochemistry, ELISA
and gene expression raw data. Raw data generated from gross and
microscopic studies of tumours, digital image analysis for measuring
the surface areas of neoplastic lesions, immunohistochemistry scores
of all studied molecules, ELISA data generated from serum and
colonic tissues; and data form quantitative expression of all targeted
genes. (XLSX 674 kb)
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